PharmaLeaders

As the landscape of drug discovery becomes increasingly complex, the generation and ownership of data in partnerships between Big Pharma and AI-driven biotechs are creating new headaches for dealmakers. Today, the ones and zeros required to train AI models for better drug target selection have become a highly valuable currency in biopharma transactions. When structuring major agreements, AI drug hunters face intricate negotiations to ensure their platforms can continue to learn and advance.

The FDA is actively championing a transition to real-time clinical trial monitoring, aiming to eliminate costly administrative delays and dramatically accelerate the timeline for new drug approvals. While the prospect of getting life-saving therapies to patients faster is a massive win for the entire healthcare industry, the underlying mechanics of this shift reveal a deeper structural issue.

It’s no secret that pharma marketers want in on the massive audiences found on platforms like TikTok and Instagram. But partnering with influencers in the highly regulated pharmaceutical space is complicated. Right now, there isn’t a definitive FDA rulebook for influencer campaigns. That leaves marketers and their Medical, Legal, and Regulatory (MLR) teams operating in a frustrating legal gray area. Every single campaign becomes a tightrope walk.

We live in an age of infinite information. From wearable trackers to viral nutritional ‘hacks,’ the path to wellness should be clearer than ever. Yet, a new study reveals that for most Americans, the noise is becoming deafening. A recent comprehensive survey of 4,000 U.S. adults, conducted by Kantar on behalf of Abbott, has uncovered a sobering reality: instead of empowering us, the current health landscape is fueling a sense of ‘information overload’ and financial anxiety.

The 26th annual DTC National is excited to return to Boston, April 21-23, 2026. The DTC National is the only event that solely focuses on the nuances of direct-to-consumer advertising in the Rx Pharmaceutical sector. LEARN MORE

Future Pharma is where pharma’s marketing, sales, and commercial leaders come together to tackle the challenges shaping patient and HCP engagement today. Through peer-led discussions and intimate, collaborative formats, attendees gain practical insights teams can apply immediately. LEARN MORE

ReImagine is the go-to experience for pharma and biotech marketers ready to rethink strategy, embrace innovation, and drive measurable results. LEARN MORE

« All Events Fierce Pharma Engage is where senior leaders in Pharma Marketing, PR & Communications, Medical Affairs, and Business Development & Licensing (BD&L) come together for strategic collaboration, candid conversation, and meaningful connection. This West Coast event offers an intimate, highly curated experience—designed to maximize interaction and unlock innovation through every conversation. LEARN MORE

« All Events Reuters Events Digital Health 2026 brings together the voices driving healthcare’s digital transformation, from hospital executives and policymakers to technologists and frontline clinicians. Let’s accelerate the shift to real-world AI adoption, prove the value of digital health, overcome data and infrastructure barriers, and most importantly, empower the workforce with smarter tools to improve patient access. LEARN MORE

Building on the momentum of its January pill launch, Novo Nordisk has secured a major regulatory win this March with the FDA approval of Wegovy HD. This 7.2 mg injectable dose of semaglutide arrives via the federal National Priority Voucher program, a fast-track framework designed to expedite medical products deemed essential to U.S. interests.